Continuing Education Lectures (CELs)
In-Person CELs will be taught in Phoenix, AZ. All times shown below are Pacific Daylight Time (PDT). Virtual attendees must adjust for their local time.
If a CEL is given virtually you will be sent a link to watch the CEL virtually from home or your hotel room. There will NOT be a room on-site at the convention center to watch the CEL.
If a CEL is given in person, you can participate in the course in person or virtually. If you are attending virtually, you will be sent a link to watch it LIVE through the SignalWire platform. If you are attending in person, the course will take place at the Phoenix Convention Center.
AAHP is evaluating the number of Continuing Education Credits awarded for each of the CEL courses based on technical content. Course instructors will be able to provide this information at the time of the presentation. This information will also be made available on the AAHP recertification site after data entry is completed.
Monday, July 26, 6:45 AM – 7:45 AM
CEL-M1: The 1976 Hanford Americium Accident: Then and Now
Eugene H. Carbaugh, CHP
On August 30, 1976 an americium-241 ion exchange column exploded in a Hanford Site waste management facility causing significant damage to the hood containing the column, extensive facility radiological contamination, and spraying an operator with highly contaminated nitric acid and debris. The worker underwent medical treatment for acid burns, as well as wound debridement, extensive personal skin decontamination and long-term DTPA chelation therapy for decorporation of americium-241. Because of the contamination levels and prolonged decontamination efforts, care was provided for the first three months at a unique emergency decontamination facility with gradual transition to the patient’s home occurring over another two months. The accident underwent an extensive investigation as to cause, response, lessons learned, therapy, and dosimetry, and has been well documented in numerous reports and journal articles. The worker incurred the largest recorded internal deposition of americium-241 and became known in the press as The Atomic Man. The lessons learned with regard to patient treatment and effectiveness of therapy still form the underlying philosophy of treatment for transuranic-contaminated injuries. Changes in infrastructure and facilities as well as societal expectations make for interesting speculation as to how responses might differ today.
CEL-M2: VIRTUAL – Working with emergency responders
A. Karam, CHP
There are a lot of health physicists working with emergency responders – or planning on working with emergency responders in the event of a radiological or nuclear emergencies. This can be incredibly rewarding, or amazingly frustrating, depending on what both sides expect from each other and how they adjust to working together. Responders have a broader mission, they have to be aware of a wider variety of concerns, and they’re often not nearly as interested in the details of our profession as we think they ought to be. In this CEL we’ll talk about some of these differences and how to use this understanding to work effectively with the cops and firefighters who will rely on us in the event of a radiological or nuclear emergency.
Tuesday, July 27, 6:45 AM – 7:45 AM
CEL-T: Therapeutic Uses Nuclear Medicine Pharmaceuticals
Mike Stabin, NV5/Dade Moeller and RADAR, Inc.
There are many radiopharmaceuticals used in nuclear medicine therapy. Some are called ’theranostics’, which means the integration of a diagnostic test with a specific therapeutic intervention. The diagnostic test should identify patients who will likely respond to a particular therapy, fail to respond to a given drug or eventually exhibit adverse events, while the therapeutic application seeks to treat a specific disease. This session will describe the applications of several radiopharmaceuticals, including the well-established I-131 NaI In the treatment of hyperthyroidism and thyroid therapy, the use of Y-90 microspheres in the treatment of hepatic cancers, and newer therapies, including Lu-177 DOTATATE for neuroendocrine tumors and Ra-223 chloride for bony metastases. Clinical successes will be discussed, but the focus will be on the radiation dosimetry aspects.
Wednesday, July 28, 6:45 AM – 7:45 AM
CEL-W: NRRPT: Advantages to Membership
Karen Barcal, NRRPT
The NRRPT provides many advantages to its members, including a synergistic relationship with the HPS. This CEL will talk to the history of the organization and its relationships with other professional organizations, the advantages to becoming a Registered Radiation Protection Technologist, and membership requirements. It will also speak to the realized benefits and experiences as a member of the NRRPT, HPS and AAHP.
Thursday, July 29, 6:45 AM – 7:45 AM
CEL-TH: Chemical Interactions and How They Can Complicate Decontamination